Mechanism of Jianpixiaoke Recipe in Treating Type 2 Diabetes Based on Network Pharmacology and Molecular Docking Authors: Huan Li, Wenrong An, Chengcheng Huang, Guowei Fang, Yanqin Huang Published: 2025 ABSTRACT ObjectiveUsing network pharmacology and molecular docking technology to analyze the potential mechanism of the Jianpixiaoke recipe (JPXK recipe) in the treatment of type 2 diabetes mellitus (T2DM).MethodThis study searched and screened the active ingredients and corresponding T2DM‐related targets of different herbs in JPXK recipe from multiple databases. Venn was used to screen the intersection targets of JPXK recipe targets and T2DM targets, and the intersection targets were imported into the STRING database to construct a PPI network. In addition, clustering and topology analysis were also used to analyze PPI networks. At the same time, a composite target network was constructed using Cytoscape software. Then, we further carried out GO and KEGG enrichment analysis on the targets and carried out molecular docking verification on key chemical ingredients and hub targets. Finally, the effect of this prescription on T2DM was verified through animal experiments.ResultThis study screened a total of 366 targets for the JPXK recipe, 1886 T2DM‐related targets, and 214 intersecting targets. The active ingredients of the JPXK recipe were quercetin, isorhamnetin, luteolin, berberine, kaempferol, etc. Potential hub targets were ESR1, JUN, SRC, PIK3R1, FOS, MAPK1, AKT1, RELA, and MAPK3. The main pathways of the JPXK recipe in treating T2DM included the MAPK signaling pathway, cAMP signaling pathway, tumor necrosis factor signaling pathway, Toll‐like receptor signaling pathway, etc. Molecular docking results showed that quercetin and luteolin combined best with the hub gene. JUN, FOS, AKT1, RELA, and MAPK3 interacted well with these critical ingredients. Animal experiments verified that the JPXK recipe had a good hypoglycemic effect.ConclusionThis study revealed the active ingredients and potential molecular mechanism of the JPXK recipe in the treatment of T2DM, which provides valuable experience in future clinical trials. 1. Introduction Type 2 diabetes mellitus (T2DM) was a chronic metabolic disease characterized by long‐term hyperglycemia. Its pathological factors were insulin resistance (IR), impaired islet function, etc. [1]. According to the data released by the International Diabetes Federation (IDF) in 2021, China had become the country with the most significant number of diabetes mellitus (DM). In the past 10 years, DM patients in China have increased from 90 million to 140 million. The number of DM patients in China is expected to reach 174.4 million in 2045 [2]. It can be seen that prevention and treatment of T2DM are particularly important. Traditional Chinese Medicine (TCM) has been proven to be extremely effective in treating DM [3]. The prevention and treatment of DM with TCM have incomparable advantages, such as considering both specimens, overall regulation, stable curative effect, improving the quality of life, and is widely recognized in the clinical and experimental [4]. The research team adheres to Professor Yanqin Huang’s concept of “spleen deficiency causes diabetes” and founded the JPXK recipe which was from the classic famous “Xiaoke recipe” [5]. “JPXK recipe” consisted of Astragalus membranaceus (Huangqi, HQ), Coptis chinensis Franch (Huanglian, HL), Radix trichosanthis (Tianhuafen, THF), Rehmannia glutinosa (Shengdihuang, SDH), Eupatorium fortunei Turcz (Peilan, PL), and Cyathula officinalis Kuan (Chuanniuxi, CNX). All the TCMs in the JPXK recipe conformed to the pharmacological action and conventional dosage in the Pharmacopoeia of China. The recipe for invigorating the spleen and eliminating thirst has the effects of invigorating the spleen and qi, promoting blood circulation and removing blood stasis, clearing heat, and promoting fluid production, and was in line with the theory of Chinese medicine in treating DM. Confirmed by later clinical research that the application of specific dosages of JPXK recipe, as a safe and effective TCM recipe, could alleviate chronic inflammation by regulating the metabolites of gut microbiota, brain‐gut peptide, and adipocytokines, increasing the content of short chain fatty acids, thereby improving the rate of reaching the standard of blood pressure, blood sugar, and blood lipid in patients with metabolic syndrome, effectively improving the function of pancreatic islet β cells, promoting insulin secretion, and improving IR [6]. Experimental research confirmed that the application of specific dosages of JPXK recipe could regulate the intracellular transport pathway of cTAGE5/TANGO1, promote insulin synthesis and secretion, and improve Endoplasmic reticulum stress [7]. In order to further explore the hub targets and potential mechanisms of action of the JPXK recipe in the treatment of T2DM, we conducted this study. Network pharmacology was a novel discipline based on system biology, molecular information science, pharmacology, and other aspects [8]. It had the characteristics of comprehensiveness and system integrity. It could analyze the multilevel network relationship of “molecular–target–pathway–disease” and clarifies the mechanism of Chinese herbal medicine remedies diseases from biological molecules and genes [9]. Molecular docking was also a new technology to predict the effectiveness of drug design according to the binding mode and affinity between molecules by simulating the binding between ligand molecules and receptor proteins [10]. With the unceasing improvement and development of network pharmacology and molecular docking, it has become a justifiable method for the research and development of TCM. And it is broadly used in the design of standard Chinese medicine compounds. The mechanism of TCM in the treatment of diseases will be sharper, and it equally provides a theoretical basis for the innovation of new drugs in the future. This study explored the targets and pathways of the JPXK recipe in the treatment of T2DM through network pharmacology and molecular docking to clarify the mechanism of the JPXK recipe in the treatment of T2DM. The research technology is shown in Figure 1. To explore the flowchart of the mechanism of the JPXK recipe in the treatment of T2DM. Abbreviation: Huangqi(HQ), Astragalus membranaceus; Huanglian(HL), Coptis chinensis Franch; Tianhuafen(THF), Radix trichosanthis; Shengdihuang(SDH), Rehmannia glutinosa; Peilan(PL), Eupatorium fortunei Turcz; Chuanniuxi(CNX), Cyathula officinalis Kuan. 2. Materials and Methods 2.1. Effective Ingredients in the JPXK Recipe Six herbs in the JPXK recipe were searched in the TCMSP database (https://old.tcmsp-e.com/tcmsp.php) to screen for effective active ingredients. But the effective active ingredients of SDH were not found in the database. The relevant chemical ingredients of SDH were supplemented by consulting the literature. The chemical ingredients of the JPXK recipe were imported into TCMSP. ADME includes the absorption, distribution, metabolism, and excretion of drugs. The higher the OB and DL values, the higher the absorption rate of the drug by the human body, which means the higher the available value of the drug. According to the pharmacokinetic ADME standard, all the ingredients were screened out for potentially effective ingredients according to the standards of oral bioavailability (OB) ≥ 30% and drug‐like (DL) ≥ 0.18. At the same time, the chemical ingredients that were effective but did not meet the screening conditions were searched on CNKI (https://www.cnki.net) and PubMed website (https://pubmed.ncbi.nlm.nih.gov/) to supplement them. Eventually, the effective ingredients of the JPXK recipe were obtained. 2.2. Targets Related to Effective Ingredients Targets of the effective ingredients in the JPXK recipe were searched from the “Related Targets” of TCMSP. Considering the targets provided by TCMSP might be incomplete, the structural information of active ingredients was supplemented through PubChem database (https://pubchem.ncbi.nlm.nih.gov/), then the targets from the Swiss Target Prediction (https://www.swiss.target.prediction.ch/) and STITCH (https://stitch.embl.de/) were retrieved in this study, which could predict the targets of the active ingredients in the JPXK recipe. Swiss Target Prediction was a database for predicting molecular targets based on the similarity of 2D and 3D structures and the binding results with ligands [11]. In Swiss Target Prediction, the species was set to “Homo sapiens,” and the probability was no less than 0.6. STITCH was a database that integrates multiple literature and biological pathways to predict drug targets and their affinity [12]. In STITCH, the species was set to “Homo sapiens,” and the confidence score was ≥ 0.6. Eventually, the target in the JPXK recipe was imported into the UniProt database (https://www.uniprot.org/), limited the research species to “Homo,” converted the target into the corresponding gene name, and standardized it. 2.3. T2DM‐Related Targets Take “type 2 diabetes mellitus” as the search keyword in GeneCards database (https://www.genecards.org/), TTD database (https://db.idrblab.net/ttd/), OMIM database (https://www.omim.org/), DrugBank database (https://go.drugbank.com/), NCBI database (https://www.ncbi.nlm.nih.gov/), CTD database (https://ctdbase.org/), and PharmGKB database (https://www.pharmgkb.org/) to select potential targets of T2DM. After merging 7 disease databases targets, delete the duplicate targets, and take the union set of the obtained targets as the disease candidate targets. The gene names corresponding to the targets were searched in the UniProt database, and the T2DM‐related targets were standardized. 2.4. Network of “JPXK Recipe–Effective Ingredients–Intersection Targets–T2DM” Using VENNY 2.1 software (https://bioinfogp.cnb.csic.es/tools/venny/) to screen the intersection targets of JPXK recipe and T2DM targets, and draw a Venn diagram. The obtained JPXK recipe–T2DM intersection targets, the effective ingredients of corresponding Chinese medicine and disease were input into Cytoscape 3.9.0 software to construct the “JPXK recipe–effective ingredients–intersection targets–T2DM” network. 2.5. Networks of Protein–Protein Interaction (PPI) 2.5.1. PPI Network of T2DM–JPXK Recipe and Hub Targets Network of T2DM–JPXK Recipe The intersection targets protein of JPXK recipe–T2DM obtained in 2.4 was imported into the STRING database (https://string-db.org/) to construct a PPI network. The biological species were set as “Homo sapiens,” and the minimum confidence was 0.900. Simultaneously, the free points were hidden, and their parameters were selected as the default format. The drawn PPI network graphics and TSV files were downloaded and saved. Cytoscape 3.9.0 was used to construct the intersection target network of JPXK recipe–T2DM, and the Cytohubba plug‐in was used to filter hub genes. The top 10 genes generated by the maximum neighborhood component (MNC) method were hub genes. In each node in the interactive network, the degree value was used to measure the number of connections with other nodes, which often reflected the significance of nodes [13]. 2.5.2. PPI Network of T2DM and Cluster Analysis of T2DM The PPI network of T2DM‐related targets was constructed by importing the T2DM‐related targets into the STRING database. The biological species was also set as “Homo sapiens,” and the minimum confidence was 0.900. Concurrently, the free points were hidden, and the parameters were selected as the default format. The PPI network graphics and TSV files were downloaded and saved. Cluster analysis can better filter out useful data, greatly improving the feasibility. The obtained PPI network was imported into Cytoscape 3.9.0, and the MCODE plug‐in was used for cluster analysis of the PPI network to select the same or similar nodes and protein complexes. When using the MCODE plug‐in in Cytoscape, the cut‐off value of node score = 0.2, k core = 2, maximum depth = 100, and degree cut‐off value (minimum score threshold) = 2 were set as the filtering conditions, and took the targets of the first five clusters for further GO and KEGG analysis. 2.6. GO and KEGG Enrichment Analysis Using R 4.1.2 software, the symbols of the intersection targets of JPXK recipe–T2DM were converted into IDs, then Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) were analyzed on them. The upshots were visualized, and the corresponding bar graph and bubble graph were plotted to analyze the possible mechanism of JPXK recipe treatment T2DM from the biological function and signaling pathway perspective. GO was a classification of gene functions, which is used to describe the properties of genes, including physical process (BP), cellular component (CC), and molecular function (MF). KEGG was a database based on gene and functional information, primarily used to analyze the function of genes and the chief metabolic pathways. GO and KEGG enrichment analysis were based on p < 0.05 to prepare the most prominent KEGG enrichment pathway. 2.7. Molecular Docking Molecular docking between hub targets and key chemical ingredients was conducted. The ligand files of vital chemical ingredients were downloaded from the PubChem database and imported into Chem3D software for spatial structure transformation and energy optimization. The files were exported in MOL2 format and then saved in PDBQT format after processing by AutoDockTools software. The gene ID of the hub target was retrieved from the UniProt database, and the 3D structure of the protein receptor corresponding to the hub gene was obtained in the PDB database (https://www.rcsb.org/), and the corresponding PDB format file was downloaded. The macromolecular receptor file of the hub target was imported into AutoDockTools software for removing water molecules and hydrogenation, and the file was saved in PDBQT format. Ultimately, the hub targets and effective active ingredients were docked with AutoDock‐Vina software, and the binding energy was used as the docking evaluation index. For this research, 5 groups with the lowest binding energy were filtered for data visualization by Pymol software. 3. Experimental Verification 3.1. Experimental Materials 3.1.1. Experimental Animals Thirty‐six healthy SPF male Wistar rats, 4 weeks old, body weight (130 ± 10) g, purchased from Beijing Weitong Lihua Laboratory Animal Technology Limited Company, certificate number: SCXK (Beijing) 2016‐0006, raised in Shandong Animal Experiment Center, Affiliated Hospital of Shandong University of TCM. The ambient temperature was 18∼26°C, and the humidity was 60%∼70%. Keep breathing smoothly and had a circadian rhythm. The experiment passed the ethics review of the Affiliated Hospital of Shandong University of TCM, review number: AWE‐2019‐001. 3.1.2. Experimental Drugs and Reagents JPXK recipe (30 g of HQ, 9 g of HL, 12 g of THF, 12 g of SDH, 12 g of PL, 9 g of CNX, TCM granules, Jiangyin Tianjiang Pharmaceutical Limited Company). Streptozotocin (STZ) (batch number: #18883‐66‐4), Sigma Company, USA; Rat Insulin ELISA Kit (batch number: #CSB‐E05070r), Rat Glucagon ELISA Reagent Box (batch number: #CSB‐E12800r); sodium citrate (batch number: #2018010203), Tianjin Zhiyuan Chemical Reagent limited company; citric acid (batch number: #2018‐09‐16), Tianjin Dingshengxin Chemical Limited Company. 3.1.3. Experimental Instrument Wenhao blood glucose meter and supporting blood glucose test strips (Johnson & Johnson (China) Medical Equipment Limited Company); Leica Immunofluorescence Microscope DM2500 (Leica, Germany). 3.2. Modeling and Drug Delivery Twelve rats were randomly selected as a control group and fed with common feed throughout the whole process. The model group was fed with SPF grade high‐sugar and high‐fat diet for 8 weeks [14]. Then, the model group was fasted for 12 h without water and received a one‐time intraperitoneal injection of STZ (concentration 35 mg/kg), and the control group was intraperitoneally injected with an equal volume of citric acid buffer (0.1 mmol/L, pH = 4.3). After 72 h, blood was collected from the tail vein to measure the fasting blood glucose (FBG) of the rats in the model group. The FBG values of the rats in the model group and JPXK recipe group were higher than those in the control group and higher than 16.7 mmol/L (p < 0.05), indicating that the modeling was successful [14]. The 24 successfully modeled rats were randomly divided into a model group and a JPXK recipe group, with 12 rats in each group. Refer to the equivalent dose conversion formula for adults (60 kg) and animals: DB = DA × KA/KB (DA represents the known dose in humans, DB represents the unknown dose in rats, KA and KB represent human and the body shape coefficient of rats, respectively), JPXK recipe group was given Chinese medicine decoction 3.125 g/kg by gavage. The control group and model group were given 3.125 g/kg 0.9% sodium chloride solution by gavage. 3.3. Pancreatic Tissue Collection and Sample Processing Assays At the end of the experiment, the rats were dehydrated for 2 h, fasted for 12 h, then weighed, anesthetized by intraperitoneal injection of 2% pentobarbital sodium (0.2 mL/100 g), and dissected. 5 mL of blood was collected from the abdominal aorta, centrifuged at 4°C at 3000 r/min for 10 min, the upper serum was taken and placed in a refrigerator at −20°C. The pancreas specimen of appropriate size was taken from each group and fixed in 4% formaldehyde solution for immunofluorescence. 3.4. Determination of FBG, Fasting Serum Insulin (FINS), Serum Glucagon (GC), and IR Index (HOMA‐IR) in Rats The Wenhao blood glucose meter was used to measure the changes in FBG in the treatment process; the FINS and GC levels of the rats were detected by the rat insulin Elisa kit, and HOMA‐IR = FBG × FINS/22.5 was calculated. 3.5. Detection by Immunofluorescence The rat pancreatic tissue fixed in 4% formaldehyde was embedded in paraffin and sliced into pancreatic specimens with a thickness of 3 μm. After incubation and PBS treatment, the distribution of insulin and glucagon in pancreatic tissue was detected by a fluorescence microscope. The immunofluorescence used in this experiment was a positive control. 3.6. Statistical Analysis Statistical analysis of the data was performed using SPSS 26.0 software. All measurement data were expressed as x¯ ± s. Differences within groups were compared by independent samples t‐test, differences between groups were analyzed by one‐way analysis of variance (one‐way ANOVA), and p < 0.05 indicated that the differences were statistically significant. In this study, post hoc tests (t‐tests) were used to correct for significant ANOVA. 4. Results 4.1. Effective Chemical Ingredients of JPXK Recipe Based on database search and literature search, the chemical ingredients were screened by OB ≥ 30% and DL ≥ 0.18: 20 ingredients of HQ, 14 ingredients of HL, 2 ingredients of THF, 7 ingredients of SDH, 12 ingredients of PL, and 4 ingredients of CNX. Ingredients with high gold content or vigorous activity reported in the literature that did not meet the above screening requirements were equally included. These ingredients included astragaloside I, astragaloside II, astragaloside III, astragaloside IV, gamma‐aminobutyric acid, gamma‐aminobutyric acid, catalpol, rehmannioside A, Stachyose, acteoside, HMF, gamma‐aminobutyric acid, ecdysteron, beta‐sitosterol. In the end, the active ingredients of the JPXK recipe were 25 active ingredients of HQ, 14 active ingredients of HL, 3 active ingredients of THF, 13 active ingredients of SDH, 12 active ingredients of PL, and 5 active ingredients of CNX. In this study, duplicate active ingredient were first deleted, and then active ingredient whose official targets could not be found in the UniProt database were deleted. Finally, 50 active ingredients were obtained (which are in Table 1). Table 1Effective chemical ingredients of JPXK recipe.DrugMolldMolNameOBDLHQMOL000211Mairin55.380.78HQMOL000239Jaranol50.830.29HQMOL000296Hederagenin36.910.75HQMOL000033(3S,8S,9S,10R,13R,14S,17R)‐10,13‐dimethyl‐17‐[(2R,5S)‐5‐propan‐2‐yloctan‐2‐yl]‐2,3,4,7,8,9,11,12,14,15,16,17‐dodecahydro‐1H‐cyclopenta[a]phenanthren‐3‐ol36.230.78HQMOL000354Isorhamnetin49.60.31HQMOL0003713,9‐di‐O‐methylnissolin53.740.48HQMOL0003745′‐hydroxyiso‐muronulatol‐2′,5′‐di‐O‐glucoside41.720.69HQMOL0003787‐O‐methylisomucronulatol74.690.30HQMOL0003799,10‐dimethoxypterocarpan‐3‐O‐beta‐D‐glucoside36.740.92HQMOL000380(6aR,11aR)‐9,10‐dimethoxy‐6a,11a‐dihydro‐6H‐benzofurano[3,2‐c]chromen‐3‐ol64.260.42HQMOL000387Bifendate31.10.67HQMOL000392Formononetin69.670.21HQMOL000398Isoflavanone109.990.30HQMOL000417Calycosin47.750.24HQMOL000422Kaempferol41.880.24HQMOL000433FA68.960.71HQMOL000438(3R)‐3‐(2‐hydroxy‐3,4‐dimethoxyphenyl)chroman‐7‐ol67.670.26HQMOL000439Isomucronulatol‐7,2′‐di‐O‐glucosiole49.280.62HQMOL0004421,7‐Dihydroxy‐3,9‐dimethoxy pterocarpene39.050.48HQMOL000098Quercetin46.430.28HQMOL000401astragalosideI46.790.11HQMOL000403astragalosideII46.060.13HQMOL000405astragalosideIII31.830.10HQMOL000407astragalosideIV22.500.15HQMOL000388Gamma‐aminobutyric acid24.090.01HLMOL001454Berberine36.860.78HLMOL013352Obacunone43.290.77HLMOL002894Berberrubine35.740.73HLMOL002897Epiberberine43.090.78HLMOL002903(R)‐Canadine55.370.77HLMOL002904Berlambine36.680.82HLMOL002907Corchoroside A_qt104.950.78HLMOL000622Magnograndiolide63.710.19HLMOL000762Palmidin A35.360.65HLMOL000785Palmatine64.600.65HLMOL000098Quercetin46.430.28HLMOL001458Coptisine30.670.86HLMOL002668Worenine45.830.87HLMOL008647Moupinamide86.710.26THFMOL004355Spinasterol42.980.76THFMOL006756Schottenol37.420.75THFMOL000388Gamma‐aminobutyric acid24.090.01SDHMOL001525Daucosterol36.910.75SDHMOL002813Aucubin35.560.33SDHMOL000359Sitosterol36.910.75SDHMOL000449Stigmasterol43.830.76SDHMOL012254Campesterol37.580.71SDHMOL000519Coniferin31.110.32SDHMOL002819Catalpol5.070.44SDHMOL003730Rehmannioside A25.950.87SDHMOL000732Stachyose3.250.59SDHMOL003333Acteoside2.940.62SDHMOL000748HMF45.070.02SDHMOL000388Gamma‐aminobutyric acid24.090.01SDHMOL000358Beta‐sitosterol36.910.75PLMOL000006Luteolin36.160.25PLMOL000359Sitosterol36.910.75PLMOL000363Amyrin palmitate32.680.30PLMOL000449Stigmasterol43.830.76PLMOL0005847‐acetoxy‐8‐hydroxy‐9‐isobutyryloxythymol33.390.18PLMOL0005889‐acetoxy‐8,10‐epoxy‐6‐hydroxythymol 3‐O‐angelate61.440.21PLMOL000592Dammaradienyl acetate46.520.82PLMOL000595Eupatoriopicrin76.780.36PLMOL000596[(3S,4aR,6aR,6aR,6bR,8aR,12S,12aR,14aR,14bR)‐4,4,6a,6b,8a,12,14b‐heptamethyl‐11‐methylene‐1,2,3,4a,5,6,6a,7,8,9,10,12,12a,13,14,14a‐hexadecahydropicen‐3‐yl] acetate43.080.74PLMOL000604Eupaformosanin50.200.52PLMOL000605Taraxasteryl palmitate33.840.31PLMOL000358Beta‐sitosterol36.910.75CNXMOL012286Betavulgarin68.750.39CNXMOL012298Rubrosterone32.690.47CNXMOL000358Beta‐sitosterol36.910.75CNXMOL000098Quercetin46.430.28CNXMOL002212Ecdysterone5.300.82Abbreviations: CNX, Cyathula o%cinalis Kuan; HL, Coptis chinensis Franch; HQ, Astragalus membranaceus; PL, Eupatorium fortunei Turcz; SDH, Rehmannia glutinosa; THF, Radix trichosanthis. Effective chemical ingredients of JPXK recipe. Abbreviations: CNX, Cyathula o%cinalis Kuan; HL, Coptis chinensis Franch; HQ, Astragalus membranaceus; PL, Eupatorium fortunei Turcz; SDH, Rehmannia glutinosa; THF, Radix trichosanthis. 4.2. Prediction of Potential Targets of Effective Ingredients of JPXK Recipe The “Related Targets” module was selected in the TCMSP database to obtain the corresponding targets of the effective ingredients of the JPXK recipe. A total of 366 gene targets of the JPXK recipe were obtained after merging and deduplication (as shown in Table 2). Table 2Effective ingredients and related targets of JPXK recipe.Traditional Chinese MedicineEffective ingredientTargetTraditional Chinese MedicineEffective ingredientTargetHQ19605SDH10169HL12363PL7195THF332CNX5277Abbreviations: CNX, Cyathula o%cinalis Kuan; HL, Coptis chinensis Franch; HQ, Astragalus membranaceus; PL, Eupatorium fortunei Turcz; SDH, Rehmannia glutinosa; THF, Radix trichosanthis. Effective ingredients and related targets of JPXK recipe. Abbreviations: CNX, Cyathula o%cinalis Kuan; HL, Coptis chinensis Franch; HQ, Astragalus membranaceus; PL, Eupatorium fortunei Turcz; SDH, Rehmannia glutinosa; THF, Radix trichosanthis. 4.3. Targets of T2DM Taking “type 2 diabetes mellitus” as the keyword, 1039 targets in GeneCards database, 184 targets in the OMIM database, 83 targets in the TTD database, 157 targets in the DrugBank database, 957 targets in the NCBI database, 235 targets in CTD database, and 24 targets in PharmGKB database were retrieved in the disease database. The obtained T2DM‐related targets were combined, duplicate targets were eliminated, and 1886 disease‐related action targets was obtained (as shown in Figure 2(a)). By using VENNY 2.1 software, 366 JPXK recipe targets and 1886 T2DM‐related disease targets were crossed, and a Venn plot was drawn to obtain 214 intersection targets (as shown in Figure 2(b)). (a): Targets Venn map of T2DM‐related disease databases. (b): Intersection targets of JPXK recipe and T2DM. Abbreviation: drug represented JPXK recipe, disease represented T2DM. (a) (b) 4.4. Network of “JPXK Recipe–Effective Ingredients–Intersection Targets–T2DM” The multidirectional network of “JPXK recipe–effective ingredients–intersection targets–T2DM” of JPXK recipe–T2DM was constructed by Cytoscape 3.9.0 software. The outcomes revealed that the network contained 268 nodes and 964 edges, including 47 effective ingredients and 214 intersection targets. The screening was carried out according to the degree values. Luteolin, kaempferol, isorhamnetin, formononetin, beta‐sitosterol, 7‐O‐methylisomucronulatol, berberine, calycosin, and stigmasterol were the top 10 chemicals with the degree values of 143, 65, 60, 37, 36, 29, 28, 25, 24, and 21, respectively. These chemical constituents might play a vital role in treating T2DM with the JPXK recipe (as shown in Figure 3). Network construction of “JPXK recipe–effective ingredients–intersection targets–T2DM”. Orange diamond represents the intersection targets, and the area of the node represents its degree value, indicating the importance of the node. Abbreviation: HQ, Astragalus membranaceus; HL, Coptis chinensis Franch; THF, Radix trichosanthis; SDH, Rehmannia glutinosa; PL, Eupatorium fortunei Turcz; CNX, Cyathula officinalis Kuan. HHC, the common components of HQ, HL, and CNX; SPC, the common components of SDH, PL, and CNX; HTS, the common components of HQ, THF, and SDH; SP1 and SP2, the common components of SDH and PL. HQ included HQ1, HQ2, HQ3, HQ4, HQ5, HQ6, HQ7, HQ8, HQ9, HQ10, HQ11, HQ12, HQ13, HQ14, HQ15, HHC, and HTS. HL included HL1, HL2, HL3, HL4, HL5, HL6, HL7, HL8, HL9, HL10, HL11, and HHC. THF included THF1, THF2, THF3, and HTS. SDH included SDH1, SDH2, SDH3, SDH4, SDH5, SDH6, SPC, HTS, SP1, and SP2. PL included PL1, PL2, PL3, PL4, PL5, SPC, SP1, and SP2. CNX included CNX1, CNX2, CNX3, SPC, and HHC. HQ1, MOL000033; HHC, MOL000098; HQ2, MOL000211; HQ3, MOL000239; HQ4, MOL000296; HQ5, MOL000354; HQ6, MOL000371; HQ7, MOL000378; HQ8, MOL000379; HQ9, MOL000380; HQ10, MOL000387; HTS, MOL000388; HQ11, MOL000392; HQ12, MOL000417; HQ13, MOL000422; HQ14, MOL000433; HQ15, MOL000442; HL1, MOL000622; HL2, MOL000785; HL3, MOL001454; HL4, MOL001458; HL5, MOL002668; HL6, MOL002894; HL7, MOL002897; HL8, MOL002903; HL9, MOL002904; HL10, MOL002907; HL11, MOL013352; THF1, MOL004355; THF2, MOL006756; SPC, MOL000358; SP1, MOL000449; SP2, MOL000359; SDH1, MOL000519; SDH2, MOL000748; SDH3, MOL002813; SDH4, MOL002819; SDH5, MOL003333; SDH6, MOL012254; PL1, MOL000006; PL2, MOL000584; PL3, MOL000588; PL4, MOL000595; PL5, MOL000604; CNX1, MOL002212; CNX2, MOL012286; CNX3, MOL012298. 4.5. Network Construction of PPI 4.5.1. PPI Network of T2DM–JPXK Recipe and Network of “Hub Targets–Key Ingredients–Herbs–T2DM” The intersection targets of 214 JPXK recipe–T2DM were imported into the String database for PPI analysis. The consequences exhibited that the network contained 214 nodes and 848 edges, with an average node degree of 7.93 (as shown in Figure 4 (a)). The downloaded PPI network corresponding TSV file was imported into Cytoscape 3.9.0 software, and the Cytohubba plug‐in in the Cytoscape platform was used to identify the hub gene (as shown in Figure 4(b)). The top 10 hub targets between JPXK recipe and T2DM were ESR1, JUN, SRC, PIK3R1, FOS, MAPK1, AKT1, TP53, RELA, and MAPK3. Among them, SRC, PIK3R1, MAPK1, TP53, AKT1, and MAPK3 was also important target for T2DM, confirming the effectiveness of the JPXK recipe in treating T2DM. PPI network of 10 hub targets had 10 nodes and 45 edges; the average node degree was 9, and the p‐value was 0.000138 (as shown in Figure 4(c)). Identification of T2DM and JPXK recipe central genes. (a) PPI network of T2DM and JPXK recipe intersection targets. The network had 214 nodes and 848 edges. (b) Cytoscape map of T2DM and JPXK recipe intersection targets. (c) Hub targets of T2DM and JPXK recipe. A “Hub targets–key ingredients–herbs–T2DM” network was constructed based on the active ingredients related to hub targets. This network had 35 nodes and 73 edges (5 herbs, 19 key ingredients, 10 hub targets, and 1 disease). It could be seen that HQ had the most effective ingredients acting on the hub targets, suggesting that HQ had a good hypoglycemic effect. Quercetin, luteolin, berberine, kaempferol, and isorhamnetin were the critical components determined by the common targets–active ingredients network, which might be the material basis for treating T2DM with the JPXK recipe (as shown in Figure 5). Network construction of “Hub targets–key ingredients–herbs–T2DM”. Circular nodes represent diseases, V‐shaped nodes represent hub targets, hexagonal nodes represent key ingredients related to hub targets, and triangular nodes represent herbs. The size and color of each node vary according to their degrees. Abbreviation: HQ, Astragalus membranaceus; HL, Coptis chinensis Franch; SDH, Rehmannia glutinosa; PL, Eupatorium fortunei Turcz; CNX, Cyathula officinalis Kuan. HHC, the common components of HQ, HL, and CNX; SPC, the common components of SDH, PL, and CNX. HHC, MOL000098; HQ5, MOL000354; HQ6, MOL000371; HQ7, MOL000378; HQ9, MOL000380; HQ11, MOL000392; HQ12, MOL000417; HQ13, MOL000422; HL2, MOL000785; HL3, MOL001454; HL4, MOL001458; HL5, MOL002668; HL6, MOL002894; HL7, MOL002897; SPC, MOL000358; SDH1, MOL000519; SDH4, MOL002819; PL1, MOL000006; CNX2, MOL012286. 4.5.2. Construction of PPI Network and Cluster Analysis of T2DM‐Related Targets The String database analyzed the PPI network of 1886 T2DM‐related targets. The effects showed that the network contained 1716 nodes and 8385 edges, with an average node degree of 9.77 (as shown in Figure 6(a)). PPI network and cluster analysis of disease targets. (a) PPI network of T2DM targets. (b) Visualization of PPI network core targets. The red nodes in the middle represent the 10 targets with the maximum degree value. (c) The first five clustering diagrams from the PPI network of T2DM targets. The PPI network was introduced into Cytoscape 3.9.0, and the 10 targets with the most significant representation of red nodes in the middle (SRC, PIK3R1, MAPK3, PIK3CA, MAPK1, EP300, TP53, STAT3, AKT1, and CTNNB1) played a central role in the occurrence and progress of T2DM. The PPI network of T2DM‐related targets was clustered using the MCODE plug‐in in Cytoscape. That was why we got 48 clusters. We chose the top five clusters (As shown in Figure 6(b, c) and Table 3). Table 3Cluster analysis of PPI networks composed of T2DM‐related targets.ClusterScoreNodesEdgesGene symbol112.38732384 IL2,IL2RA,IL2RB,IL2RG,VEGFA,IRS2,IL23A,OSM,MMP9,MMP1,LBP,IL10,FGF2,IL17A,POMC,IL6,LCN2,MET,TGFB1,TIMP1,ERBB2,MAP2K1,EGF,MMP3,MMP2,KRAS, ERBB3,PDGFRB,PIK3CB,IGF1R,NRAS,IRS1 210.76569732 CCL5,CCL3,IL18,IL1B,CCL2,CXCL10,PRKCZ,MYC,FGFR2,FGFR3,PIK3R1,PIK3CA,SHC1,JAK2,SOCS3,KIT,MAPK8,IL12A,IL1A,TNF,HRAS, KITLG,CXCL2,EGFR,SRC,SP1,HIF1A,MTOR, APOC3,NR1H3,PPARA, CETP,APOB, APOE,TSC1,LAMA2,CPT1A,MLST8,PRKAA2,DAG1,PRKAA1,LAMB2,LAMB3,PRKAG1,DMD,PRKAG2,PRKAB2,SMPD1,PRKAB1,LCAT, RAPSN,ITGA1,PAK1,LPA,LAMC2,LPL,TSC2,APOC2,FABP1,ACTA1,APOC1,APOA5,PRKAG3,JUN,INSR,SDC2,PRKCD, PTPN1,SMAD3 38.46470584 FOXO3,CXCL8,AGTR2,GNAS,RET,EPO,ADRB2,CCR5,HTR2C,ADRA1B,SOX2,RXRA,IL4R,RORA, BIRC5,FOS,BDNF,SOS1,INS,PIK3CG,FLT1,FLT4,IGF1,HDAC1,NKX2-5,SMAD5,BMP2,BMPR2,BMPR1A,GATA4,SMAD4,GRB2,NOTCH1,PTPN11,IL13,CAV1,IL6R,KDR,SMAD2,FOXO1,EP300,STK11,BRAF, CBLB,PRKCB,TEK,YWHAQ,FGF1,CD40,CD40LG,PTEN, MAPK1,ESR1,BMP7,BMP4,MAPK9,PTPN2,STAT5B,MAPK3,ARNT,KL,PLCG1,KLB,RPS6KB1,NR3C1,TLR4,FGF19,NTRK2,CDKN2A,SMARCA4 47.429852 MT-ND4L,MT-ND4,MT-ND2,MT-ND1,MT-CO3,MT-CO1,MT-ATP6,NDUFS2 57.27334240 CDK4,TBP,RBPJ,LRP5,WNT5B,CCND2,WNT9A,WNT5A,GLI2,WNT3A,LRP6,WNT2B,WNT4,RELA,TYK2,CDK2,MDM2,CDKN2B,XRCC3,HDAC2,CDKN1B,TCF7L2,IFNB1,HDAC3,BRCA1,CTNNB1,RUNX2,EZH2,TP53,BRCA2,ATM,CDKN1A,CCND1,GSK3B Cluster analysis of PPI networks composed of T2DM‐related targets. 4.6. GO and KEGG Analysis 4.6.1. GO and KEGG Enrichment Analysis of JPXK Recipe–T2DM Intersection Targets The intersection target of JPXK recipe–T2DM was converted By R 4.1.2 software, and the intersection target was performed by GO analysis. We got 3125 GO entries, including 2804 BP entries, 94 CC entries, and 227 MF entries. Since the p‐value represents enrichment and aboriginality, the first 10 items with the smallest p‐value in BP, CC, and MF were selected to make the GO bio function enrichment bar chart and bubble chart by R 4.1.2 software. The results presented that the BP of the intersection target genes of JPXK recipe and T2DM mainly concentrated in response to xenobiotic stimulation, wound healing, response to oxidative stress, response to nutrient levels, and response to lipopolysaccharide. CC was primarily focused on membrane raft, membrane microdomain, vesicle lumen, transcription regulator complex, and apical part of the cell. MF was mainly centered on DNA‐binding transcription factor binding, RNA polymerase II–specific DNA‐binding transcription factor binding, ubiquitin‐like protein ligase binding, cytokine receptor binding, and phosphatase binding. GO analysis results are shown in Figure 7(a). The enrichment of core targets in BP is shown in Figure 7(b), the enrichment of core targets in CC is shown in Figure 7(c), and the enrichment of core targets in MF is shown in Figure 7(d). GO analysis of intersection targets of JPXK recipe and T2DM. (a) (b) (c) (d) By using KEGG enrichment analysis, we obtained 187 KEGG signal pathways. The outcomes demonstrated that the signal pathway of the intersection targets between JPXK recipe and T2DM majorly touched upon lipid and atherosclerosis, the role of the AGE‐RAGE signaling pathway in diabetic complications, PI3K‐Akt signaling pathway, IL‐17 signaling pathway, fluid shear stress, and atherosclerosis, and endocrine resistance (As shown in Figure 8(a)). The enrichment of core targets in important pathways is shown in the figure below. The enrichment results of core targets in significant pathways are shown in Figure 8(b) . The results showed that the pathway most significantly enriched PIK3R1, MAPK1, MAPK3, and AKT1 targets. (a) KEGG analysis of intersection targets of JPXK recipe and T2DM; (b) enrichment results of hub targets in significant pathways. (a) (b) 4.6.2. GO and KEGG Analysis of T2DM‐Related Targets GO and KEGG analyses were performed on the target points of five clusters obtained in Section 4.5.2 for T2DM disease. We ultimately received 3138 BP entries, 224 MF entries, 96 CC entries, and 182 KEGG pathways. The top 10 meaningful GO and the top 30 meaningful KEGG pathways in BP, MF, and CC are shown in the figure, respectively. GO analysis revealed that the BP of T2DM was mainly affected by the positive regulation of kinase activity, positive regulation of MAPK cascade, peptidyl‐tyrosine phosphorylation, and peptidyl‐tyrosine modification, positive regulation of protein kinase activity, and regulation of protein serine/threonine kinase activity. The CC related to T2DM could be found in the transcription regulator complex, membrane raft, membrane microdomain, transferase complex, transferring phosphorus‐containing groups and protein kinase complex activated. The MF of T2DM was related to cytokine activity, signaling receptor activator activity, receptor‐ligand activity, cytokine receptor binding, and transmembrane receptor protein kinase activity. GO analysis results are shown in Figure 9(a). The enrichment of core targets in BP is shown in Figure 9(b), the enrichment of core targets in CC is shown in Figure 9(c), and the enrichment of core targets in MF is shown in Figure 9(d). GO analysis of T2DM‐related targets. (a) (b) (c) (d) KEGG analysis displayed that the significant avenues of approach related to T2DM were PI3K‐Akt signaling pathway, FoxO signaling pathway, endocrine resistance, MAPK signaling pathway, mTOR signaling pathway, and AGE‐RAGE signaling pathway in diabetic complications (as shown in Figure 10(a)). The enrichment of core targets in important pathways is shown in Figure 10(b). The results showed that the pathway most significantly enriched in PIK3R1, MAPK1, and MAPK3. (a) KEGG analysis of T2DM‐related targets; (b) enrichment results of hub targets in significant pathways. (a) (b) 4.6.3. Selection and Analysis of Crucial GO and KEGG of T2DM–JPXK Recipe After comparing and analyzing the KEGG and GO functions of disease targets and common targets of JPXK recipe and T2DM, we found 2173 overlapping BPs, 112 overlapping MFs, 42 overlapping CCs, and 159 overlapping KEGG pathways. The hub genes selected by the MNC method might play a more meaningful role through the JPXK recipe in treating T2DM. Hence, we decided on GO with more than five hub targets and KEGG with more than 6 hub targets. This study obtained 16 critical BP, 4 vital CC, and 34 key KEGG pathways. Since no more than 5 hub targets were found in CC, only 1 CC containing more than 4 hub targets was selected, and chosen in the following analysis. The key MF was mainly related to DNA binding transcriptional activation activity (GO:0001216), DNA binding transcriptional activation activity, RNA polymerase II specificity (GO:0001228), RNA polymerase II specificity, DNA binding transcription factor binding (GO:0061629), and DNA binding transcription factor binding (GO:0140297). The key CC were transcriptional regulators (GO:0005667). The critical BP was mainly involved in the reaction of lipopolysaccharide (GO:0032496), molecular response to bacterial sources (GO:0002237), cell response to biological stimulation (GO:0071216), oxidative stress (GO:0006979), reactive oxygen species (GO:0000302), nutritional response (GO:0031667), transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178), etc. This suggests that the prevention of DM might be closely related to intestinal flora [15]. Studies had shown that intestinal flora was related to insulin release. Changes in the structure of intestinal flora will lead to changes in material metabolism in the body, damage to the intestinal wall, and infiltration of a large number of microorganisms into the blood and tissues, inducing inflammatory reactions and IR, resulting in disorders of blood glucose metabolism in T2DM patients [16, 17]. Some studies indicated that DM originated from “intestinal heat”, and the JPXK recipe was used to treat T2DM by the invigorating spleen and clearing heat, which was consistent with the network pharmacology mechanism in this study [18]. The clear KEGG enrichment pathway indicated that the JPXK recipe could play a synergistic role in the intervention of T2DM in protecting the function of islet β cells by regulating multiple signaling pathways such as immunity, hormones, and inflammatory reactions, anticancer, and anti‐infection. The prominent KEGG pathway is shown in Table 4. Table 4T2DM and its overlapping KEGG enrichment pathways with the JPXK recipe.IDDescriptionT2DM significant signal pathwayJPXK recipe ‐ T2DM significant signal pathwayp.adjustCountNumber of hub genesp.adjustCountNumber of hub geneshsa04010MAPK signaling pathway9.30E‐244667.09E‐12327hsa04024cAMP signaling pathway4.11E‐061967.84E‐05177hsa04668TNF signaling pathway8.86E‐142262.95E‐17267hsa04919Thyroid hormone signaling pathway1.01E‐233267.03E‐11207hsa04915Estrogen signaling pathway8.39E‐132371.58E‐07178hsa04917Prolactin signaling pathway1.37E‐232673.37E‐14198hsa04926Relaxin signaling pathway1.99E‐172778.82E‐16268hsa01522Endocrine resistance2.05E‐333787.92E‐20279hsa04620Toll‐like receptor signaling pathway1.59E‐152364.48E‐12207hsa04625C‐type lectin receptor signaling pathway1.11E‐172565.86E‐15237hsa04660T Cell receptor signaling pathway1.11E‐172565.99E‐13217hsa04662B Cell receptor signaling pathway2.85E‐101662.07E‐06127hsa05418Fluid shear stress and atherosclerosis1.41E‐162765.06E‐23347hsa05417Lipid and atherosclerosis1.32E‐213881.06E‐28469hsa04722Neurotrophin signaling pathway2.71E‐172661.88E‐08177hsa04210Apoptosis1.22E‐081871.62E‐12238hsa04380Osteoclast differentiation6.86E‐101962.58E‐11217hsa05205Proteoglycans in cancer4.23E‐355067.09E‐17337hsa05235PD‐L1 expression and PD‐1 checkpoint pathway in cancer5.91E‐162262.39E‐11187hsa05203Viral carcinogenesis7.87E‐163172.90E‐05177hsa05208Chemical carcinogenesis ‐ reactive oxygen species6.66E‐143075.36E‐15328hsa05207Chemical carcinogenesis–receptor activation4.02E‐173389.79E‐25429hsa05210Colorectal cancer9.31E‐293268.41E‐17237hsa05224Breast cancer2.38E‐414977.12E‐12238hsa05130Pathogenic Escherichia coli infection4.97E‐051662.69E‐07206hsa05131Shigellosis3.14E‐112873.48E‐08248hsa05135Yersinia infection8.38E‐142478.98E‐11218hsa05142Chagas disease6.91E‐182563.18E‐17257hsa05171Coronavirus disease ‐ COVID‐193.99E‐112762.20E‐09256hsa05170Human immunodeficiency virus 1 infection9.28E‐102464.38E‐08227hsa05163Human cytomegalovirus infection1.01E‐234166.43E‐15327hsa05166Human T‐cell leukemia virus 1 infection4.57E‐223971.10E‐12298hsa05161Hepatitis B5.32E‐263887.76E‐20339hsa05167Kaposi sarcoma–associated herpesvirus infection3.35E‐223781.85E‐18349 T2DM and its overlapping KEGG enrichment pathways with the JPXK recipe. By constructing the PPI network of T2DM and JPXK recipe, combined with Cytohubba identification of hub targets, GO and KEGG results were sorted and analyzed. The effective ingredients of the JPXK recipe in the treatment of T2DM were quercetin, luteolin, berberine, isorhamnetin, and kaempferol, and the essential targets were ESR1, JUN, SRC, PIK3R1, FOS, MAPK1, AKT1, TP53, RELA, and MAPK3. 4.7. Molecular Docking Results Ten hub targets and 5 key chemical ingredients were respectively used as receptors and ligands. Binding energy can reflect the stability of protein receptor binding with small molecular ligands. The higher the absolute value of binding energy, the more stable the binding between receptor and ligand. The binding energy of −5.0 kcal/mol was set as a threshold for good binding between receptor and ligand. The ligand with the best binding to the receptor (the lowest energy) was selected according to the binding energy. The molecular docking results of the five groups of receptors with the lowest binding energy with ligands are shown in Figure 11 and Table 5. Molecular docking of key ingredients and hub targets. Table 5Molecular docking results of hub targets and key ingredients.Hub targets (PDB ID)QuercetinLuteolinBerberineIsorhamnetinKaempferol(kcal/mol)(kcal/mol)(kcal/mol)(kcal/mol)(kcal/mol) ESR1(1ERE) −8.5−7.9−6.7−7−7.7 JUN(1A02) −8.6−8.7−9.2−8−8.3 SRC(1A07) −6.3−7.3−6.8−6.7−5.9 PIK3R1(1A0N) −7.5−7.3−6.5−6.9−7.3 FOS(1FOS) −8.3−8.4−8.4−8.3−8.1 MAPK1(1PME) −6.6−7.4−6.5−7.2−7.4 AKT1(7NH4) −8.2−8.1−7.5−6.8−7.6 TP53(1A1U) −6.3−6.4−6.5−6.1−5.7 RELA(INFI) −8.6−9.1−7.6−8−7.9 MAPK3(6GES) −7.9−8.3−7.7−7.7−8 Molecular docking results of hub targets and key ingredients. Quercetin and luteolin combined best with the hub targets. JUN, FOS, AKT1, RELA, and MAPK3 interacted well with these critical ingredients. These indicated that some effective ingredients in the JPXK recipe had good binding properties with protein targets. 4.8. FBG, FINS, GC Results and HOMA‐IR Level Compared with before treatment, after treatment, the blood sugar of the JPXK recipe group decreased, suggesting that the JPXK recipe had a good hypoglycemic effect. Compared with the control group, the FBG, HOMA‐IR, and GC values of the model group were significantly increased (p < 0.05), and the FINS value was decreased (p < 0.05). Compared with the model group, the FBG and GC values of the JPXK recipe group were significantly decreased (p < 0.05), and the FINS value was significantly increased (p < 0.05). The results are shown in Table 6. The concentration changes of FINS and GC in rats in each group are shown in Figures 12(a) and 12(b). Table 6Comparison of the levels of FBG, FINS, GC, and HOMA‐IR.Group n FBG(mmol/L)FINS(mIU/L)GC(PG/L)HOMA‐IRBefore administrationafter administrationControl group124.49 ± 0.164.67 ± 0.1620.61 ± 0.54152.78 ± 6.594.28 ± 0.16Model group1226.38 ± 1.24∗∗△ 26.96 ± 1.31∗∗△ 12.61 ± 0.62∗∗△ 228.75 ± 9.10∗∗△ 15.12 ± 1.18∗∗△ JPXK recipe group1227.37 ± 1.38∗∗△ 20.90 ± 1.13∗∗△ 18.00 ± 0.39∗∗△ 203.55 ± 6.82∗∗△ 16.72 ± 0.93∗∗△ Note: Compared with the control group. FINS, Fasting serum insulin; GC, Serum glucagon; HOMA‐IR, Homeostatic Model Assessment for Insulin Resistance.Abbreviation: FBG, fasting blood glucose. ∗ p < 0.05. ∗∗ p < 0.01; compared with the model group. △ p < 0.05. Comparison of the levels of FBG, FINS, GC, and HOMA‐IR. Note: Compared with the control group. FINS, Fasting serum insulin; GC, Serum glucagon; HOMA‐IR, Homeostatic Model Assessment for Insulin Resistance. Abbreviation: FBG, fasting blood glucose. ∗ p < 0.05. ∗∗ p < 0.01; compared with the model group. △ p < 0.05. Animal experiment results. (a) Fasting insulin value of each group. (b) Glucagon value of each group. (c–e) Immunofluorescence diagram of each group. Abbreviation: FINS, Fasting serum insulin; GC, Serum glucagon. (a) (b) (c) (d) (e) 4.9. Immunofluorescence Observation of Pancreatic Tissue Distribution Insulin was stained with red fluorescence in the cytoplasm, and glucagon was stained with green fluorescence. Immunofluorescence showed that the insulin in the JPXK recipe group was more distributed in the pancreas than the model group, which indicated that after the treatment of T2DM rats with the JPXK recipe, the islet function recovered and the level of insulin secretion was improved. The results are shown in Figures 12(c)–12(e). 5. Discussion T2DM was a chronic metabolic disease characterized [19]. Long‐term high blood sugar leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, blood vessels, and nerves. The JPXK recipe as a TCM compound significantly affected T2DM. Our team had confirmed through clinical and experimental studies that the JPXK recipe could lower blood sugar and improve pancreatic islet β cell function. Clinical studies had verified that the application of specific dosages of JPXK recipe could effectively reduce blood glucose, regulate blood lipid, improve IR, and preserve islet function in T2DM patients [20]; 689 patients had been treated with the JPXK recipe [21]. Experiments demonstrated that the application of specific dosages of JPXK recipe could significantly heighten the number of islet β cells in DM rats, inhibit the apoptosis of islet β cells [22], enhance autophagy of islet β cells, and promote insulin secretion, thus protecting islet function [23]. Concurrently, 7 therapeutic targets and biological processes of the application of specific dosages of JPXK recipe in the treatment of T2DM were found to adopt using microRNA omics technology, which was verified by experiments in later studies, enriching the research mechanism of JPXK recipe in the treatment of T2DM [24]. In our previous work, we applied network pharmacology to analyze the mechanism and potential pathways of HQ and HL (the main drugs in the JPXK recipe) and confirmed their effectiveness in the treatment of DM. HQ could ameliorate the insulin signaling pathway by upregulating casein kinase activity, regulating glucose and lipid metabolism, and enhancing IR, to treat T2DM [25]; HL could treat T2DM through an anti‐inflammatory effect [26]. At the same time, we conducted network pharmacology and molecular docking with the drug pair of HL and PL in the recipe for invigorating the spleen and eliminating thirst. The results showed that the drug pair could treat T2DM through anti‐inflammatory, regulating glucose and lipid metabolism, etc. [27]. These studies laid the foundation for the study of network pharmacology and molecular docking of JPXK recipe. In this study, by constructing the PPI network of the JPXK recipe and T2DM intersection targets, we discovered that ESR1, JUN, SRC, PIK3R1, FOS, MAPK1, AKT1, TP53, RELA, and MAPK3 were the hub targets for the treatment of T2DM. These targets were mainly related to hosting immunity, glucose and lipid metabolism, and inflammatory response. The MAPK signaling pathway covered them, the cAMP signaling pathway, the tumor necrosis factor signaling pathway, and the Toll‐like receptor signaling pathway. We noted that only 6 hub targets overlap with 10 essential targets of T2DM. Based on the hub targets analysis, vital active ingredients and the main significant KEGG pathways explore the potential mechanism of the JPXK recipe in the treatment of T2DM. 5.1. Analysis of Hub Targets The activation of the estrogen receptor gene (ESR1) could regulate hepatocyte factor, delay hepatic steatosis, and reduce IR for the sake of achieving the purpose of lowering blood glucose [28]. AKT1 was a crucial protein factor of the phosphatidylinositol 3 kinase (PI3K)/AKT pathway [29], which could induce downstream molecules such as glucose transporters to improve glucose uptake, improve glucose utilization, participate in glucose metabolism and lipid metabolism, and regulate blood glucose balance [30]. It has been confirmed that AKT1 could be expressed in many insulin‐sensitive tissues such as the liver, skeletal muscle, and fat [31]. PIK3R1 was a member of the PI3K/AKT signaling pathway and participates in insulin metabolism. The increased expression of PIK3R1 could promote the expression of pyruvate dehydrogenase kinase 4, inhibit glucose uptake and glycogen synthesis, delay insulin signal, and increase blood glucose in the body [32]. JUN was a signal molecule connecting inflammation and IR. JUN will be activated under long‐term hyperglycemia, promote the release of inflammatory factors, induce inflammation, enhance the expression of related apoptotic genes, and damage the function of islet cells [33]. Studies had shown that after the knockout of the JUN gene in DM mice, blood glucose was significantly reduced, insulin signal transduction was enhanced, and islet function was effectively improved [34]. As a tumor suppressor gene, TP53 was related to body metabolism [35]. TP53 could regulate glucose transporters on the cell membrane to enhance IR and blood glucose balance. Furthermore, it could affect glucose metabolism by intervening in glycolysis and other processes [36]. SRC was associated with a viral infection and tumors and played a role in activating the protein tyrosine kinase (PTK) family. Studies had shown that after SRC knockout in mice, under cold conditions, with the increase of heat production in mice, FBG level decreases and insulin sensitivity increases [37]. FOS was a proto‐oncogene that promoted apoptosis of pancreatic islet β cells, leading to a decrease in insulin levels in the body and the development of T2DM [38]. MAPK1 and MAPK3 belonged to a class of cytokines that could participate in inflammatory response and IR [39]. Studies had shown that MAPK1 and MAPK3 could enhance insulin secretion and regulate blood glucose stability [40]. RELA was an essential inflammatory factor, which could control the inflammatory response of cells, enhance the production of proinflammatory cytokines by macrophages, and aggravate the chronic inflammation and macrophage IR induced by a high‐fat diet [41]. Inhibition of RELA expression could increase glucose transport and consumption and improve macrophage IR [42]. 5.2. Analysis of Vital Active Ingredients Quercetin was a common ingredient of HQ, HL, and CNX. As a flavonoid, quercetin had antioxidant, anti‐inflammatory, hypoglycemic, and other pharmacological effects [43]. Research exhibited that quercetin could inhibit α‐glucosidase activity to promote glycogen synthesis and regulate the expression of AKT1 and other related apoptotic genes to improve function of islet β cell [44], as well as activate MAPK1 and MAPK3, increase insulin secretion, and improve IR, to regulate glucose metabolism [40]. Isorhamnetin had pharmacological effects such as antitumor, anti‐inflammatory, and antioxidant stress [45]. Isorhamnetin could regulate the Ras/MAPK signal pathway, lead to S‐phase arrest of PANC‐1 cells, and inhibit the proliferation of tumor cells [46]. Studies had shown that Isorhamnetin could hinder IKK/IKB/NF‐KB/iNOS signaling pathway and reduce interleukin‐1β(IL‐1β), interleukin‐6(IL‐6), and other inflammatory factors to achieve the effect of anti‐DM [47]. Luteolin had anti‐inflammatory, antioxidant, and other pharmacological effects, which could inhibit inflammatory factors such as interleukin‐1 (IL‐1) and IL‐6, promote the expression of anti‐inflammatory factors, reduce the inflammatory response, and improve IR [48, 49]. TNF signaling pathway was one of the critical pathways of inflammatory response in the body and participates in the occurrence and development of T2DM [50]. Studies had shown that luteolin could inhibit the activation of NF‐Kb in intracellularization, reducing the release of TNF‐α, which was a therapeutic effect of DM [51]. Berberine had physiological functions such as antibacterial, hypoglycemic, and lipid‐lowering, which could promote the process of islet β cell regeneration, effectively reduce IR, and could reduce the activity of maltase and sugars to reduce the postprandial blood sugar of patients with T2DM [52]. Studies had shown that berberine could heighten ghrelin and GLP‐1 in gastrointestinal hormones, increase the role of gastrointestinal hormones, and regulate glucose and lipid metabolism [52]. Berberine also could restrict the insulin gene Ins2 promoter, activate amp‐activated protein kinase (AMPK) in the liver and muscle, uphold mitochondrial uncoupling protein 2 (UCP2), increase energy consumption, and promote glucose metabolism [53]. Kaempferol had antioxidant, anti‐inflammatory, hypoglycemic, anticancer, and other pharmacological effects [54]. Kaempferol could boost glucose metabolism in skeletal muscle, inhibit liver gluconeogenesis, increase sensitivity to insulin, and promote insulin secretion to achieve the effect of treating T2DM [55]. Kaempferol also could likewise protect the islet β cells by reducing the activity of T cells and regulating Th1/Th2 [56]. Research on Fang Min and others showed that kaempferol could adjust TNF‐α, IL‐17, AGE‐RAGE, and other signal channels through critical targets such as AKT1 and TNF‐α to treat T2DM [57]. 5.3. Analysis of Critical KEGG Pathways Toll‐like receptor signaling pathway played an essential role in inflammatory response and IR in patients with DM and could regulate immune response and inflammatory response [58]. The cyclic adenosine monophosphate (CAMP)/protein kinase (PKA) signaling pathway could regulate glucose homeostasis in various ways, including glucose uptake, glycogen synthesis, and decomposition [59]. The MAPK signaling pathway involved chronic DM complications and was associated with high glucose, oxidative stress, growth factors, and other related in DM patients. Activating MAPK signaling pathway could inhibit IRS phosphorylation and increase IR [60]. As a vital path of inflammation of the body, the TNF signaling pathway was closely related to the NF‐KB signaling pathway and jointly participates in the development process of T2DM [61]. TNF‐α activates the TNF signaling pathway by combining the receptor TNFR1, raises downstream signal protein molecules, maintains the continuous activation of NF‐kB, forms an inflammatory response, and aggravates IR [62]. Thyroid hormone improves the sensitivity of the body to insulin by regulating hepatic glycogen synthesis and increasing glucose utilization, to regulate the stability of blood glucose in the body [63]. The role of the estrogen signaling pathway was mainly related to estrogen receptor (ER) mediated [64]. Studies had shown that ER could regulate PIK3/Akt signaling pathway, promote Nrf2 signal transduction, increase antioxidant enzyme levels, and inhibit oxidative damage to DM complications [65]. Human giant cell virus infections had caused damage to the body’s immune mechanism, and a large amount of islet β cells have apoptosis, which had promoted the rise of blood sugar, which had caused T2DM for a long time [66]. The infection of human immunodeficiency virus type 1 infection destroys the immune system, aggravating DM prevalence [67]. T2DM was closely related to COVID‐19. Infection of COVID‐19 by the body could lead to a massive release of proinflammatory cytokines, resulting in the chronic inflammatory reaction, and decreasing insulin secretion, thereby aggravating the risk of DM [68]. For people without DM, it might likewise increase the risk of hyperglycemia and increase the risk of critical illness [69]. The results demonstrated that the essential targets and KEGG pathways of the T2DM–JPXK recipe were all related to cancer. Research had also shown that DM was associated with numerous cancers, such as breast cancer and colorectal cancer [70], whereas the molecular mechanism of the two was unclear, which might be due to the long‐term hyperglycemia of T2DM patients, which provided nutrition for the growth of tumor cells, improved the expression of insulin‐like growth factor (IGF) and receptors in the state of IR and hyperinsulinemia, and promoted the proliferation of tumor cells, thus increasing the risk of T2DM patients suffering from tumor, which also corresponds to the KEGG pathway screened in this paper [71, 72]. It might also be the metabolic disorder of T2DM patients, increasing reactive oxygen species, and long‐term oxidative damage of DNA causes cancer [70]. At present, metformin, the first‐line drug of T2DM, had an anticancer effect [73]. In patients with hepatitis B, due to liver damage in vivo, the synthesis of liver glycogen was reduced, and the level of glucose in vivo was increased. In the case of long‐term hyperglycemia, pancreatic islet cells will work in compensation, which will lead to IR, insufficient insulin secretion, and ultimately lead of DM [74]. Zhang Huiyan considered that chronic infection of the hepatitis B virus was closely related to liver‐derived DM [75]. In summary, in this study, network pharmacology and molecular docking technology were used to preliminarily explore the complex mechanism of JPXK Recipe in treating T2DM through multicomponent, multitarget, and multichannel. The consequences demonstrated that the components of the JPXK recipe directly affected DM and might play a critical role in DM by regulating the metabolism of glucose and lipid, participating in the process of lipopolysaccharide reaction, IR, and related signal transduction. Simultaneously, the relationship between DM and cancer showed that the JPXK recipe might not only treat T2DM but also effectively prevent the occurrence of cancer. Molecular docking revealed that quercetin and luteolin combined best with the hub targets. JUN, FOS, AKT1, RELA, and MAPK3 interacted well with these critical ingredients. Animal experiments had verified that the JPXK recipe could effectively treat T2DM by lowering blood sugar and protecting islet function. Notwithstanding, this study only confirmed the participation of the JPXK recipe in hypoglycemic, anti‐inflammatory, and other mechanisms from a microperspective. Subsequent examinations will be experimentally and clinically verified to make them more credible and clinically significant. 6. Conclusion The key active ingredients of the JPXK recipe for the treatment of T2DM included quercetin [76, 77], isorhamnetin, luteolin, berberine, and kaempferol. Through the construction of the compound targets disease network, the 10 hub targets including ESR1, JUN, SRC, PIK3R1, FOS, MAPK1, AKT1, TP53, RELA, and MAPK3 were obtained. The main pathways of the JPXK recipe in treating T2DM included the MAPK signaling pathway, cAMP signaling pathway, tumor necrosis factor signaling pathway, Toll‐like receptor signaling pathway, etc. Animal experiments demonstrated that the JPXK recipe had a great hypoglycemic effect and could effectively protect the function of pancreatic islets. The therapeutic effect of the JPXK recipe in treating T2DM was mainly through regulating the host’s immune and inflammatory response, antibacterial microorganisms, regulating glucose and lipid metabolism, improving IR, etc. This study could provide a theoretical basis for further exploration of the treatment of T2DM with JPXK recipe. However, this study only explored the mechanism of action of specific TCM formulas in treating T2DM, and the theoretical basis provided in the exploration of TCM in treating T2DM had certain limitations. Disclosure All authors approved the submitted version. Conflicts of Interest The authors declare no conflicts of interest. Author Contributions Y.H. and H.L. conceived and designed this study. Y.H., H.L., and W.A. conducted data analysis and data interpretation. C.H., G.F., and H.L. conducted animal experiments and data analysis. Y.H. and H.L. conducted the statistical analysis and prepared the manuscript. All authors contributed to the article. Funding This research was supported by the National Natural Science Foundation of China (81974562), Shandong Taishan Scholar Project (tsqn202211354), Qiuhai Qian national famous traditional Chinese Medicine expert inheritance studio (National Traditional Chinese Medicine Education Letter [2022] No. 75), Shandong Key Laboratory of Traditional Chinese Medicine Efficacy and Mechanism (PKL2024C23), and Construction and Efficacy Evaluation of an Intelligent Innovation Platform for Weight Management utilizing Traditional Chinese Medicine (2025CXPT147).